2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5940 CAR-hematotox by treatment line in LBCL patients receiving CD19 CAR-T therapy: Lower risk profiles in earlier lines associate with diminished hematotoxicity and improved survival outcomes

Linus Kruk, MD, Gloria Iacoboni, MD2, Julia Katharina Scholz, MD3, Tobias Tix, MD4, Kieron White5, Giulia Rappa6, Samar Shamas7, Alessandra Holzem, MD8, Kayleen Shi9, Giulia Magno, MD10, Sophia Stock, MD11, Simon Voelkl, PhD12, Sergi Camarillas, MD13, Veit Leonhard Buecklein, MD, PhD14, Andreas Mackensen, MD15, Michael Von Bergwelt, MD16, Fabian Müller, MD, PhD17, Pere Barba, MD, PhD18, Marion Subklewe I, MD19, Kai Rejeski, MD20
1 LMU University Hospital, LMU Medizin, Munich, Germany
2 Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d’Hebron University Hospital, Barcelona, Spain
3 Deutsches Zentrum Immuntherapie, Erlangen, Germany, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
4 LMU University Hospital, LMU Medizin, Munich, Germany
5 Gene Center, LMU Munich, Munich, Germany
6 Gene Center, LMU Munich, Munich, Germany
7 LMU University Hospital, LMU Medizin, Munich, Germany
8 LMU University Hospital, LMU Medizin, Munich, Germany
9 LMU University Hospital, LMU Medizin, Munich, Germany
10 Gene Center, LMU Munich, Munich, Germany, German Cancer Consortium (DKTK), Munich, Germany, LMU University Hospital, LMU Medizin, Munich, Germany
11 German Cancer Consortium (DKTK), Munich, Germany, Institute of Clinical Pharmacology, LMU Medizin, Munich, Germany, LMU University Hospital, LMU Medizin, Munich, Germany, The Bavarian Cancer Research Center (BZKF), Munich, Germany
12 Deutsches Zentrum Immuntherapie, Erlangen, Germany, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
13 Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d’Hebron University Hospital, Barcelona, Spain
14 Gene Center, LMU Munich, Munich, Germany, LMU University Hospital, LMU Medizin, Munich, Germany
15 Deutsches Zentrum Immuntherapie, Erlangen, Germany, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
16 LMU University Hospital, LMU Medizin, Munich, Germany
17 Deutsches Zentrum Immuntherapie, Erlangen, Germany, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
18 Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d’Hebron University Hospital, Barcelona, Spain
19 Gene Center, LMU Munich, Munich, Germany, German Cancer Consortium (DKTK), Munich, Germany, LMU University Hospital, LMU Medizin, Munich, Germany, The Bavarian Cancer Research Center (BZKF), Munich, Germany
20 German Cancer Consortium (DKTK), Munich, Germany, LMU University Hospital, LMU Medizin, Munich, Germany, Memorial Sloan Kettering Cancer Center, New York, United States, The Bavarian Cancer Research Center (BZKF), Munich, Germany

Objectives: Chimeric antigen receptor T-cell (CAR-T) therapy has been successfully introduced into second-line treatment of large B-cell lymphoma (LBCL). However, it remains ill-defined whether hematologic toxicity and infectious burden meaningfully differ across treatment lines and if the pre-lymphodepletion risk score, CAR-HEMATOTOX (CAR-HT), retains predictive value when applied in earlier lines.

Methods: This retrospective multi-center study included adults with r/r LBCL treated with standard-of-care CD19 CAR-T at three large-volume European centers (Munich, Barcelona, Erlangen). Treatment lines were counted as lines of treatment administered prior to CAR-T indication (2L, 3L, 4L+) excluding bridging or holding therapy. The study analyzed CRS and ICANS (ASTCT grading), hematotoxicity (EHA/EBMT ICAHT grading), infections and lymphocyte phenotypes. Univariate and multivariate Cox regression was used to analyze progression-free and overall survival (PFS, OS). ROC analyses evaluated discriminative performance. NRM was assessed by Fine-Gray test, accounting for competing events. Exploratory plasma proteomics were performed on prospectively collected pre-infusion serum samples from a patient subset (n=90) using the Olink proximity extension assay (IO96 panel).

Results: The cohort comprised 407 LBCL patients (308 de novo DLBCL, 99 transformed) stratified into second line (2L, 26.8%), third line (3L, 46.7%) or 4th-or-further-line (4L+, 26.5%). As expected, CAR-T product selection differed markedly by line, with axi-cel and liso-cel predominant in 2L and 3L, tisa-cel in 4L+. Baseline LDH elevation and administration of bridging or holding therapy were comparable across lines. Advanced treatment lines were associated with high-risk CAR-HT scores (2L: 31.4%, 3L: 44.8%, 4L+: 63.3%; p<0.001) and significantly worse ECOG performance status.

No significant differences in CRS or ICANS severity emerged. However, we identified treatment-line-dependent patterns of hematologic toxicity, with deeper and longer neutropenic nadirs noted in the 4L+ cohort, while 2L and 3L patients displayed earlier neutrophil recovery (Early-ICAHT; p=0.049, Late-ICAHT; p=0.031). RBC transfusion rates rose from 23% to 43% to 48% (p=0.03). CAR-HT retained discriminatory performance for ICAHT across every treatment line in ROC analyses (AUC 0.75-0.88). The overall infection incidence in the first 30 days rose successively across lines from 38.7% to 43.9% to 73.7% (p<0.001), as did infection severity (grade ³3: p=0.001). A numeric trend toward increased 1-year NRM emerged in advanced lines (2.9% vs 4.0% vs 7.6%, p=0.1).

PFS and OS were both significantly inferior in the 4L+ cohort, while comparison of 2L over 3L did not reach statistical significance (median PFS 25.1 vs 16.4 vs 3.1 months; log-rank p<0.001; median OS not reached for 2L and 3L, 12.6 months in 4L+; p<0.001). High-risk CAR-HT scores stratified PFS across all treatment lines, with the most favorable outcomes observed in low-risk 2L and 3L groups. Notably, even in 2L, high-risk CAR-HT patients had poor outcomes, and CAR-HT remained an independent predictor of PFS in multivariate analysis (p=0.002), while treatment line did not.

Exploratory immune cell profiling did not show significant differences across treatment lines, except for lower T helper cell counts at apheresis (p=0.032) and lower pre-lymphodepletion leukocyte counts (p=0.035) in 4L+ compared with 2L. CAR T-cell expansion kinetics did not differ significantly between 2L, 3L, and 4L+ patients. Proteomic profiling showed enrichment of stromal and inflammatory programs in 2L (Up: CXCL12, ANGPT1/TIE2, CD40L, and IL-1α), consistent with a protective endothelial state. Conversely, 4L+ showed relative enrichment of apoptotic and immunosuppressive features (Up: CASP8 and Galectin-1). Of interest, 3L and 4L+ proteomics resembled each other more than 2L.

Conclusion: Our data indicate that patients treated with CD19 CAR-T in earlier lines are enriched for low CAR-HT risk, which - rather than treatment line itself - accounts for lower hematotoxicity, fewer severe infections, and improved outcomes in these patients. The independent prognostic value of CAR-HT in multivariate analysis supports host-level hematopoietic reserve and baseline inflammation as the true drivers of outcome. These findings warrant prospective investigation of risk-informed treatment strategies, particularly for patients with high baseline CAR-HT risk.

Linus Kruk, MD: No relevant conflicts of interest to declare.